P.S.K Biosciences has established a function-defined natural exosome therapeutics platform based on MSC-derived exosome subtyping. Instead of developing heterogeneous mixed MSC exosomes, the platform uses a proprietary TFF and SEC-based purification workflow to reproducibly separate MSC-derived exosomes into functionally defined subpopulations.
This strategy transforms exosome drug development from mixed vesicle products into defined therapeutic candidates with clearer biological identity, indication-specific potency characterization, and improved CMC controllability.
Two distinct function-defined MSC-derived exosome subpopulations powering differentiated therapeutic programs.
A function-defined exosome subpopulation with anti-inflammatory, anti-fibrotic, and immunomodulatory potential.
A function-defined exosome subpopulation with potential in cell proliferation, vascular regeneration, and tissue repair.
The platform supports a function-defined natural exosome drug portfolio:
RP-ILD, AE-COPD, IBD
Stroke, heart failure, Alzheimer’s disease, Parkinson’s disease
S1 has demonstrated encouraging clinical signals in an investigator-initiated RP-ILD study, including oxygenation and survival improvement. These data provide early human translational evidence supporting the therapeutic potential of PSK’s function-defined anti-inflammatory exosome platform.
Positive human signals in RP-ILD
RP-ILD CT comparison
Before treatment
After treatment
Patient profile: Male, 10-year COPD history
Pulmonary findings: Bronchial wall thickening in both lungs with scattered emphysema
Together with translational and preclinical data in AE-COPD, stroke, heart failure, and neurodegenerative diseases, the platform supports both inflammation modulation and tissue repair/regeneration potential.
Building trust through transparent documentation and international regulatory engagement.
First peer-reviewed characterization of S1-sEVs and S2-sEVs from HucMSCs.
S1 (041763) and S2 (041762) filings completed by P.S.K Biosciences.
Listed as "Human Umbilical Mesenchymal Stem Cell Extracellular Vesicles" (INCI 40148).
Continued clinical evaluation in RP-ILD, AE-COPD, and regenerative indications.
